NR3C2 and hydrops fetalis: Previously, patients with HF with reduced ejection fraction (HFrEF) were recommended treatment with angiotensin-converting enzyme inhibitors (ACEi) or an angiotensin II receptor blocker (ARB) and beta-blocker (BB) combined with a mineralocorticoid receptor antagonist (MRA) [3].